ArticleInternational journal of nanomedicine2017
Synergistic interactions between antimicrobial peptides derived from plectasin and lipid nanocapsules containing monolaurin as a cosurfactant against
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Membrane-Targeted Consequences of Acetaminophen Toxicity and Off-Target Effects of Antimicrobial Peptides on Host Cell Membranes.International journal of molecular sciences · 2026Review
- Antibacterial and anti-virulence activity of eco-friendly resveratrol-loaded lipid nanocapsules against methicillin-resistant staphylococcus aureus.Scientific reports · 2025Article
- Expression and characterization of the new antimicrobial peptide AP138L-arg26 anti Staphylococcus aureus.Applied microbiology and biotechnology · 2024Article
- A novel cathelicidin TS-CATH derived fromComputational and structural biotechnology journal · 2024Article
- Antimicrobial Peptides: The Game-Changer in the Epic Battle Against Multidrug-Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Site Mutation Improves the Expression and Antimicrobial Properties of Fungal Defense.Antibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Peptides against Bacterial Pathogens: Innovative Delivery Nanosystems for Pharmaceutical Applications.Antibiotics (Basel, Switzerland) · 2023Review
- Recent Advances in the Development of Lipid-, Metal-, Carbon-, and Polymer-Based Nanomaterials for Antibacterial Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- The dual interaction of antimicrobial peptides on bacteria and cancer cells; mechanism of action and therapeutic strategies of nanostructures.Microbial cell factories · 2022Review
- Current Advances in Lipid and Polymeric Antimicrobial Peptide Delivery Systems and Coatings for the Prevention and Treatment of Bacterial Infections.Pharmaceutics · 2021Review
- Lipid Nanoparticle Technology for Delivering Biologically Active Fatty Acids and Monoglycerides.International journal of molecular sciences · 2021Review
- Recent Advances and Challenges in Nanodelivery Systems for Antimicrobial Peptides (AMPs).Antibiotics (Basel, Switzerland) · 2021Review
- Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy.Drug delivery and translational research · 2021Review
- Nanobiosystems for Antimicrobial Drug-Resistant Infections.Nanomaterials (Basel, Switzerland) · 2021Review
- Potent and Specific Antibacterial Activity againstAntibiotics (Basel, Switzerland) · 2020Article
- Shorter Antibacterial Peptide Having High Selectivity forMicroorganisms · 2020Article
- The Clinical Use of Monolaurin as a Dietary Supplement: A Review of the Literature.Journal of chiropractic medicine · 2019Article
- Characterization of theFrontiers in cellular and infection microbiology · 2019Article
- Synergistic Effect of Combinations Containing EDTA and the Antimicrobial Peptide AA230, an Arenicin-3 Derivative, on Gram-Negative Bacteria.Biomolecules · 2018Article
- Antimicrobial Peptides and Nanotechnology, Recent Advances and Challenges.Frontiers in microbiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of effective antibacterial agents for the treatment of infections caused by Gram-positive bacteria resistant to existing antibiotics, such as methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.